

**FENWICK & WEST LLP**

SAN FRANCISCO OFFICE | EMBARCADERO CENTER WEST

275 BATTERY ST., SUITE 1500 | SAN FRANCISCO, CA 94111

TEL 415.875.2300 | FAX 415.281.1350 | WWW.FENWICK.COM

FACSIMILE TRANSMISSION**OFFICIAL****CONFIDENTIAL**

DATE: 7/21/04

ATTORNEY DOCKET NO: 23714-79924S

TO:

NAME	FAX NO.	PHONE NO.
USPTO GAU 1644 Examiner Ewoldt	(703) 872-9306	

FROM: Susan T. Hubl, Ph.D.
Patent Agent

PHONE: (415) 875-2316

NUMBER OF PAGES WITH COVER PAGE: 7

ORIGINAL WILL NOT FOLLOW

MESSAGE:

US Patent Application No: 10/773,356
IDS**CAUTION - CONFIDENTIAL**

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE OR THEIR DESIGNEE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPY OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, OR IF THEY ARE NOT CLEAR,
PLEASE CALL _____ AT _____ AS SOON AS
POSSIBLE.



0001/PTO Rev. 10/95		U.S. Department of Commerce Patent and Trademark Office		Application Number	10/773,356		
TRANSMITTAL FORM <i>(to be used for all correspondence during pendency of filed application)</i>				Filing Date	FEBRUARY 5, 2004		
				First Named Inventor	WEINER		
				Group Art Unit Number	1644		
				Examiner Name	EWOLDT		
Total Number of Pages In This Submission		7	Attorney Docket Number		23714-7992/US		

ENCLOSURES (check all that apply)	
<input type="checkbox"/> Fee Transmittal Form (in duplicate) <input type="checkbox"/> Check Enclosed <input type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Response to Notice to File Missing Parts <input type="checkbox"/> Assignment & Recordation Cover Sheet <input type="checkbox"/> Declaration <input type="checkbox"/> Power of Attorney <input type="checkbox"/> Application Data Sheet <input checked="" type="checkbox"/> Information Disclosure Statement & PTO/SB/08A (5 pp) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Request for Correction of Recorded Assignment <input type="checkbox"/> Amendment/Response: [] Page(s) <input type="checkbox"/> After Final <input type="checkbox"/> Status Request <input type="checkbox"/> Revocation and Substitute Power of Attorney	<input type="checkbox"/> Issue Fee Transmittal <input type="checkbox"/> Letter to Chief Draftsperson <input type="checkbox"/> Formal Drawing(s): [] Sheet(s) of Figure(s) [] <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> After Allowance Communication to Group <input checked="" type="checkbox"/> FAX COVER SHEET <input type="checkbox"/> _____ <input type="checkbox"/> _____ <input type="checkbox"/> _____ <input type="checkbox"/> _____ <input type="checkbox"/> _____
REMARKS:	

SIGNATURE OF ATTORNEY OR AGENT			
Signature:	<i>Susan T. Hubl</i>		
Attorney/Reg. No.:	SUSAN T. HUBL, PH.D., PATENT AGENT/ REG NO. 47,668	Dated:	7/21/04

CERTIFICATE OF FACSIMILE TRANSMISSION			
I hereby certify that this correspondence, including the enclosures identified above, is being transmitted on the date shown below via facsimile to: Commissioner for Patents at the facsimile number indicated below.			
Signature:	<i>Susan T. Hubl</i>		
Typed or Printed Name:	SUSAN T. HUBL	Dated:	7/21/04
Facsimile Number:	1-703-872-8306		

23714/07992/SF/5125124.1
07/21/04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: WEINER ET AL
APPLICATION NO.: 10/773,356
FILING DATE: FEBRUARY 5, 2004
TITLE: T CELL VACCINATION FOR THE TREATMENT OF
MULTIPLE SCLEROSIS
EXAMINER: EWOLDT
GROUP ART UNIT: 1644
ATTY. DKT. NO.: 23714-07992US

RECEIVED
CENTRAL FILE UNIT
JUL 21 2004

OFFICIAL

CERTIFICATE OF FACSIMILE TRANSMISSION			
I hereby certify that this correspondence, including the enclosures identified above, is being transmitted on the date shown below via facsimile to Commissioner for Patents at the facsimile number indicated below.			
Signature:	<i>Susan T. Hubl</i>		
Typed or Printed Name:	SUSAN T. HUBL	Dated:	7/21/04
Facsimile Number:	1-703-872-9306		

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

- ☒ within three months of the filing date of the application, or date of entry into the national stage of an international application, or before the mailing date of a first office action on the merits, whichever event last occurred;
- ☒ This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application No. 09/156,509 filed on SEPTEMBER 17, 1998, and the references cited

23714/07992/SF/5125123.1
07/21/04

PATENT

therein are hereby referenced, but are not required to be provided in this application under 37 CFR § 1.98(d).

- ☒ Applicant submits that no fee is required for the consideration of this Information Disclosure Statement.

Consideration of the listed references and favorable action are solicited.

Respectfully submitted,
LESLIE WEINER ET AL

Dated: 7/21/04

By: *Susan T. Hubl*
Susan T. Hubl, Patent Agent, Reg. No.: 47,668
Fenwick & West LLP
Silicon Valley Center
801 California Street
Mountain View, CA 94041
Tel.: (415) 875-2316
Fax.: (650) 938-5200

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/773,356
		Filing Date	February 5, 2004
		First Named Inventor	Weiner et al.
		Art Unit	1644
		Examiner Name	EWOLDT
Sheet 1 of 3	Attorney Docket Number		23714-07992/US

sent 7/21/04

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document No. Number - Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A1	US-5,849,886	12-15-1998	MAATTA ET AL

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		WO 81/015225	17-10-1981	BRIGHAM AND WOMEN'S HOSPITAL ET AL
		WO 90/010448	20-09-1990	COHEN ET AL
		WO 03/024393 A2	12-09-2002	OPEXA PHARMACEUTICALS ET AL

OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
		ACHA-ORBEA, H., et al., "Limited heterogeneity of T cell receptors from lymphocytes medicating autoimmune encephalomyelitis allows specific immune intervention," <i>Cell</i> , (1988) 54: 263-273		
		BEN-NUN, A. ET AL. "The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease." <i>J. Neurol</i> (1996) 243(Suppl 1):S14-S22		
		BEN-NUN, A., ET AL., "Restricted T-Cell receptor Vβ gene usage by myelin base protein-specific T-Cell clones in multiple sclerosis: Predominant genes vary in individuals," <i>Proc. Nat. Acad. Sci USA</i> (1991) 88: 2466-2470		
		BOURDETTE, D.N., ET AL., "Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides," <i>J. Immunol.</i> (1994) 152:2510-2519		
		CHOU, Y.K., ET AL., "Immunity to TCR peptides in multiple sclerosis. II. T Cell Recognition of Vβ5.2 and Vβ6.1 CDR2 peptides," <i>J. Immunol.</i> (1994) 152:2520-2529		
		COHEN, PL. "Systemic autoimmunity" from <i>Fundamental Immunology</i> , (1999) pages 1067 and 1083. William E. Paul, editor, Lippencott-Raven, Publishers.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1448A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/773,356
		Filing Date	February 5, 2004
		First Named Inventor	Weiner et al.
		Art Unit	1644
		Examiner Name	EWOLDT
Sheet	2	of	3
		Attorney Docket Number	23714-07992/US

Sent 7/21/04

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T‡
		CORREALE, J., ET AL. "Isolation and characterization of CD8+ T-cell clones (TCCs) that recognize autologous-activated CD4+ TCCs from chronic progressive multiple sclerosis (MS) patients: implications for immunoregulation in MS," <u>Neurology</u> , (February 1996) 46: Suppl. S, p. A280	
		CORREALE, J. ET AL. "T-cell vaccination in secondary progressive multiple sclerosis," <u>Journal of Neuroimmunology</u> , (2000) 107:130-139.	
		GOLD, D.P., ET AL. "Results of a phase 1 clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCR Vβ6 CDR 2 peptide, <u>J. Neuroimmunol.</u> , (1997) 76 pp. 29-38.	
		HAFLER, D.A., ET AL. "T cell vaccination in multiple sclerosis: A preliminary report," <u>Clin. Immunol Immunopath.</u> (1992) 62(3), pp. 307-313	
		HOWELL, M.D., ET AL. "Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides," <u>Science</u> , (1989) 246:668-670.	
		LIBLAU, R., ET AL., "T cell response to myelin basic protein epitopes in multiple sclerosis patients and healthy subjects," <u>Eur. J. Immunol.</u> , (1991) 21:1391-1395.	
		LOHSE, A.W., ET AL. "Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells," <u>Science</u> (1989) 244:820-822.	
		MEDAER, R., ET AL. "Prospects for T cell vaccination in multiple sclerosis," <u>BioDrugs</u> , (1997), 8:1-5.	
		MILLER, STEPHEN D., ET AL. "The immunopathogenesis and regulation of T-cell mediated demyelinating disease," <u>Immunology Today</u> , (1994) 15:356-361.	
		MORELAND, L., ET AL. "Vaccination against rheumatoid arthritis," <u>BioDrugs</u> , (1997) 8:87-95.	
		STINISSEN, P., ET AL. "Vaccination with autoreactive T cell clones in multiple sclerosis: Overview of immunological and clinical data," <u>Journal of Neuroscience Research</u> (1996) 45:500-511.	
		VAN DER AA ET AL. "T cell vaccination in multiple sclerosis patients with autologous CSF derived activated T cells: results from a pilot study," <u>Clin. Exp. Immunol.</u> (2003) 131:155-168.	
		VAN LAAR, J., ET AL. "Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis," <u>Journal of Autoimmunity</u> , (1993) 6:159-167	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608.
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ***Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>sent 7/21/04</i>			Application No.	10/773,356	
			Filing Date	February 5, 2004	
			First Named Inventor	Weiner et al.	
			Art Unit	1644	
			Examiner Name	EWOLDT	
Sheet	3	of	3	Attorney Docket Number	23714-07992/US

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T‡
		VANDENBARK, A.A., ET AL. "T Cell receptor peptides in treatment of autoimmune disease: rational and potential," <u>J. Neurosci. Res.</u> , (1996) 43:391-402	
		VANDENBARK, A.A., ET AL. "Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis," <u>Nature</u> (1989) 341:541-544	
		WEINER, L., ET AL., "Isolation and characterization of CD8+ and gamma-delta T cells specific for autologous autoreactive CD4+ T cell clones from multiple sclerosis patients and healthy control subjects," <u>Neurology</u> , (March 1997), 48 (3) Suppl. 2, pp. A59-A60	
		ZHANG, J., ET AL. "T-cell vaccination in autoimmune diseases – from laboratory to clinic," <u>Human Immunol.</u> (1993) 38, pp. 87-96	
		ZHANG, J., J., ET AL. "MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination," <u>Science</u> , (1993) 261:1451-1454	
		ZHANG, J., ET AL. "Myelin basic protein-reactive T cells in multiple sclerosis: pathologic relevance and therapeutic targeting," <u>Cytotechnology</u> (1994) 16:181-187	
		ZHANG ET AL. In vivo clonotypic regulation of human myelin basic protein reactive T cells by T cell vaccination," <u>Journal of Immunology</u> ((1995) 155:5868-5877	
		ZHANG, J. "Multiple Sclerosis: Perspectives on Autoimmune Pathology and Prospects for Therapy," <u>Current Neurology</u> (1995) 15:115-155	

23714/07992/SF/5122822.1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809.
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ***Applicant is to place a check mark here if English language Translation is attached.